CPRX Q2 2022 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M+46.1% YoY

Gross Profit

$45M85.6% margin

Operating Income

$29M53.8% margin

Net Income

$22M40.7% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+23.3%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$26M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$267M

Total Liabilities

$26M

Stockholders' Equity

$241M

Cash & Equivalents

$211M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$36M	+46.1%
Gross Profit	$45M	$32M	+42.9%
Operating Income	$29M	$16M	+80.4%
Net Income	$22M	$12M	+77.5%

Revenue Segments

Product Revenue Net

$53M100%

License And Other Revenue

$64,0000%